Paragon Biosciences

OverviewSuggest Edit

Paragon Biosciences is a company engaged in investing in and launching of biopharmaceutical companies. It also catalyzes the progress of its portfolio companies through early-incubation services and provides clinical and regulatory guidance.
TypePrivate
Founded2010
HQChicago, IL, US
Websiteparagonbiosci.com

Latest Updates

Employees (est.) (Sept 2021)26
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Paragon Biosciences

Jeffrey S. Aronin

Jeffrey S. Aronin

Founder, Chairman & CEO
Timothy Cunniff

Timothy Cunniff

EVP, Research & Development
Patrick Morris

Patrick Morris

EVP, Legal Affairs and General Counsel
Kerensa Jimenez

Kerensa Jimenez

CEO, Health Capital
Eric Messner

Eric Messner

SVP, Business Development
Babar Ghias

Babar Ghias

EVP, Portfolio Management
Show more

Paragon Biosciences Office Locations

Paragon Biosciences has an office in Chicago
Chicago, IL, US (HQ)
330 N Wabash Ave #3500
Show all (1)

Paragon Biosciences Financials and Metrics

Summary Metrics

Founding Date

2010

Paragon Biosciences total Funding

$4 m

Paragon Biosciences latest funding size

$4 m

Time since last funding

3 years ago
Paragon Biosciences's latest funding round in August 2018 was reported to be $4 m. In total, Paragon Biosciences has raised $4 m
Show all financial metrics

Paragon Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Paragon Biosciences Online and Social Media Presence

Embed Graph

Paragon Biosciences Blogs

Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome

Paragon Biosciences’ Portfolio Company Focuses on Areas with High Unmet Needs Chicago, June 22, 2021 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced toda…

Sai Chavala, M.D., Receives ARVO Foundation Ludwig Von Sallmann Clinician-Scientist Award

Sai Chavala, M.D., Receives ARVO Foundation Ludwig Von Sallmann Clinician-Scientist Award Dr. Chavala is co-founder of CiRC Biosciences with Jeff Aronin, chairman and CEO of Paragon Biosciences Chicago, June 3, 2021—CiRC Biosciences, Inc., Co-Founder and Chief Scientific Officer Sai Chavala, M.D.…

CiRC Biosciences Announces Orphan Drug Designation for Treatment of Retinitis Pigmentosa (RP)

CiRC Biosciences Announces Orphan Drug Designation for Treatment of Retinitis Pigmentosa (RP) Cell Therapy Platform Seeks to Restore Vision for People with RP Chicago, March 10, 2021— CiRC Biosciences, Inc., a privately held cell therapy company, today announced that the U.S. Food and Drug Admini…

Paragon Biosciences Appoints Jordan Dubow as Chief Medical Officer

Chicago, February 23, 2021—With continued growth in its portfolio of life science companies, Paragon Biosciences announced the appointment of Jordan Dubow, M.D., as chief medical officer. Dr. Dubow is responsible for identifying and evaluating innovation ... Read moreParagon Biosciences Appoints Jor…

Paragon Biosciences Adds CiRC Biosciences to Expand Cell and Gene Therapy Platform

Its vision restoration technology featured in Nature and New England Journal of Medicine; CiRC is Paragon’s 7th portfolio company, with more in development Chicago, February 2, 2021 – Paragon Biosciences, a life science innovator that ... Read moreParagon Biosciences Adds CiRC Biosciences to Expand …

First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering

Speak Freely Study Investigates Ecopipam for Childhood-Onset Fluency Disorder Chicago – December 15, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency ... Read moreFirst Pa…

Paragon Biosciences Frequently Asked Questions

  • When was Paragon Biosciences founded?

    Paragon Biosciences was founded in 2010.

  • Who are Paragon Biosciences key executives?

    Paragon Biosciences's key executives are Jeffrey S. Aronin, Timothy Cunniff and Patrick Morris.

  • How many employees does Paragon Biosciences have?

    Paragon Biosciences has 26 employees.

  • Who are Paragon Biosciences competitors?

    Competitors of Paragon Biosciences include Infusion Pharma Consulting, TRAZA and Dosatsu.

  • Where is Paragon Biosciences headquarters?

    Paragon Biosciences headquarters is located at 330 N Wabash Ave #3500, Chicago.

  • Where are Paragon Biosciences offices?

    Paragon Biosciences has an office in Chicago.

  • How many offices does Paragon Biosciences have?

    Paragon Biosciences has 1 office.